Compare Corning Incorporated (GLW) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Novavax Inc — how do they compare? Corning Incorporated trades at $156.6 (market cap $131.65B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Corning Incorporated is far larger — about 72.3× Novavax Inc's market cap, and Corning Incorporated pays a 0.73% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Novavax Inc for 59 Days on average.
| GLW | NVAX | |
|---|---|---|
Market Cap | $131.65B | $1.82B |
Volume | 8,992,522 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $255.79 | $12.56 |
52-Week Low | $78.03 | $6.22 |
Typical Hold Time | 36 Days | 59 Days |
Enterprise Value | $138.52B | $1.39B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $156.69, down 3.99% amid a bearish technical signal, though fundamentals show strong recovery with 2025 revenue reaching $15.63B and net income surging to $1.60B. The company recently secured a multi-year $3B fiber supply deal with AT&T, boosting its optical communications segment. Analyst consensus remains positive with a $171.25 price target and 57% buy ratings, but technical indicators show selling pressure with support at $149.
GLW presents a mixed outlook: the AT&T deal and earnings beat streak support growth, but high valuation ratios (P/E 70.43) and bearish technicals pose near-term risks. Investors should weigh strong cash flow projections ($1.0B net CF in 2026) against patent litigation concerns and elevated debt levels. The stock offers upside to analyst targets if execution continues.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
